Cushing Disease
📧 Sign up to get email alerts when something new happens for Cushing Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies [Phase 4]
Phase 4 expanded-access study update for pasireotide shows completed status with results posted, enabling access for eligible patients in No…
-
CLINICAL_TRIALS trial_result · 2024-05-14Clinical Trial Update: Diagnostic Yield of Deep Learning Based Denoising MRI in Cushing's Disease
Clinical trial update on the diagnostic yield of a deep learning-based denoising MRI for Cushing's disease due to pituitary ACTH-secreting a…
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Treatment of Cushing's Disease With R-roscovitine [Phase 2]
Phase 2 trial evaluating R-roscovitine for Cushing's disease has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-19Clinical Trial Update: Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease [Phase 3]
Phase 3 clinical trial update evaluating efficacy and safety of osilodrostat in Cushing's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-02Clinical Trial Update: Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease [Phase 2]
Extension study evaluating safety and efficacy of pasireotide in participants with Cushing's disease (Phase 2; completed).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Safety and Efficacy of LCI699 in Cushing's Disease Patients [Phase 2]
Phase 2 trial updates the safety and efficacy of LCI699 for Cushing's disease, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2020-09-18Clinical Trial Update: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease [Phase 2]
Phase 2 clinical trial evaluating pasireotide with or without cabergoline in patients with Cushing's disease; study terminated with results …
-
FDA label_change · 2020-07-09FDA Approved: SIGNIFOR LAR — Supplemental Application (Recordati Rare Diseases, Inc.)
FDA approved a supplemental application for SIGNIFOR LAR (pasireotide) submitted by Recordati Rare Diseases, Inc., to modify the product lab…
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease [Phase 3]
Phase 3 trial update for LCI699 in Cushing's disease reports completed results on safety and efficacy.
-
FDA approval · 2020-03-06FDA Approved: ISTURISA — Original Application (Recordati Rare Diseases, Inc.)
FDA approved ISTURISA (osilodostat) through an original NDA for adults with Cushing's disease. The approval provides a new treatment option …
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly [Phase 4]
A Phase 4 clinical trial completed in 2019 evaluating management of pasireotide-induced hyperglycemia in adults with Cushing's disease or ac…
-
FDA approval · 2019-01-29FDA Approved: SIGNIFOR — Supplemental Application (Recordati Rare Diseases, Inc.)
The FDA approved a supplemental application for Signifor (pasireotide) submitted by Recordati Rare Diseases, Inc. This action expands the dr…
-
CLINICAL_TRIALS trial_result · 2018-06-19Clinical Trial Update: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. [Phase 3]
An open-label, multi-center expanded-access Phase 3 trial of subcutaneous pasireotide in patients with Cushing's disease has completed with …
-
CLINICAL_TRIALS trial_result · 2018-06-14Clinical Trial Update: Effects of Hormone Stimulation on Brain Scans for Cushing s Disease [EARLY_Phase 1]
Phase 1 study evaluating how hormone stimulation affects brain scans in Cushing's disease due to a pituitary neoplasm. The trial status is c…
-
CLINICAL_TRIALS trial_result · 2018-04-11Clinical Trial Update: Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease [Phase 3]
A Phase 3 trial evaluating monthly pasireotide for efficacy and safety in Cushing's disease has completed, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment [Phase 4]
A Phase 4 clinical trial assessing adipokine profiles in patients with Cushing's disease treated with pasireotide has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) [Phase 2]
Phase 2 clinical trial investigating rosiglitazone for newly diagnosed ACTH-secreting pituitary tumors (Cushing disease) was terminated with…
-
CLINICAL_TRIALS research · 2015-06-30Clinical Trial Update: Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease [Phase 2]
A Phase 2 clinical trial evaluating gefitinib for USP8-mutated Cushing's disease, including patients with corticotrophin adenoma.
-
FDA approval · 2015-03-17FDA Approved: SIGNIFOR — Supplemental Application (Recordati Rare Diseases, Inc.)
The FDA approved a supplemental application for Signifor (pasireotide) filed by Recordati Rare Diseases, Inc., potentially expanding its lab…
-
FDA approval · 2014-12-15FDA Approved: SIGNIFOR LAR — Original Application (Recordati Rare Diseases, Inc.)
The FDA granted original approval for Signifor LAR (pasireotide) from Recordati Rare Diseases, Inc. for the treatment of adults with Cushing…
-
CLINICAL_TRIALS trial_result · 2014-09-08Clinical Trial Update: The Factors Associated With the Recurrence in Patients With Cushing Disease
This completed clinical trial analyzes factors associated with recurrence in patients with Cushing disease.
-
CLINICAL_TRIALS withdrawal · 2014-08-04Clinical Trial Update: Mifepristone in Children With Refractory Cushing's Disease [Phase 3]
The Phase 3 trial of mifepristone in children with refractory Cushing's disease has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2013-11-20Clinical Trial Update: Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome [Phase 3]
Phase 3 trial results for mifepristone (CORLUX) in endogenous Cushing's syndrome have been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2013-02-06Clinical Trial Update: Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease [Phase 3]
Phase 3 trial evaluating safety and efficacy of different dose levels of pasireotide in patients with de novo, persistent or recurrent Cushi…
-
EMA approval · 2012-01-20European Medicines Agency recommends approval of new medicine for Cushing's disease
EMA recommends approval of a new medicine for Cushing's disease, indicating a potential new treatment option after evaluation.